Abstract library

353 results for "pnet".
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#713 Non-Functioning Pancreatic Neuroendocrine Tumors (PNET): Association with Prediabetes/Diabetes
Introduction: Neuroendocrine tumors of pancreas (PNET) are classified as functional or nonfunctional (NF) based on presence or absence of clinical syndrome associated with hormone over secretion. NF-PNETs do, however, often produce low levels of inactive hormones (pancreatic polypeptide, calcitonin or neurotensin) which do not cause any symptoms.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Etyy Osher
Keywords: NF-PNET, DM/IFG
#1111 Autophagy as a Possible Mechanism of Resistance in pNET Treatment
Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tabea Wiedmer
#1564 Well Differentiated Pancreatic Neuroendocrine Tumors (WDPNET) G3: Does the Ki67 Really Do It All?
Introduction: WDPNET G3, although not recognized by the 2010 WHO classification are far from exceptional. They also represent a great therapeutic challenge especially since their molecular drivers are unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Jerome Cros
#604 Expression of Netrin-1 and its Receptors in pNETs
Introduction: Netrin-1, a member of axon guidance molecules, and its dependence receptors (DCC, UNC5, neogenin) is involved in several cancer types (breast, neuroblastoma, colon etc) but its role in pNETs remains unknown.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Colette Roche
#646 Immunohistochemical (IHC) and Cytogenetic Approach for Improving Diagnosis and Therapy of Ewing Sarcoma (ES)/pPNET Arising in the Ileocecal Region
Introduction: ES/pPNET primary to the ileocecal region (IpPNET) have been rarely reported on and show close similarities in histology and clinical presentation with small round blue cell tumors. The EWS gene is fused to four members of the ETS family.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Md, PhD Massimo Milione
Keywords: EWS, pPnet, FEV
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
#1086 mTOR Down-Stream Signaling Pattern May Predict pNET Response to Everolimus
Introduction: NETs are rare neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The mammalian target of rapamycin (mTOR) pathway plays a central role in the regulation of cell growth, metabolism, and apoptosis representing a novel molecular target. This pathway is constitutively activated in pancreatic NETs (pNETs) providing the basis for the development of specific mTOR inhibitors as new therapeutic tools.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, Everolimus, mTOR
#1160 Exclusive Hotspot Mutation of YY1 Gene in Insulinomas and Extensive Mutation of DAXX in PNETs
Introduction: Somatic mutation of YY1 was shown in sporadic insulinoma, the main type of functional PNET. DAXX mutation occurred mainly in NF-PNET. However, YY1 and DAXX mutations in non-insulinomas and insulinomas, respectively, have not been well elucidated.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Song Y L, Qiao X W, Bai C M, Lu C M, ...
Keywords: YY1, daxx, mutation, PNET
#2235 Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
Introduction: Sunitinib has been shown to be effective in advanced pancreatic neuroendocrine tumors (PNETs) but it is not well known how dose-intensity and treatment time influence the results.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: PhD Paula Jimenez-Fonseca
Close
Notice
Important Notice:

In preparation of the upcoming 16th Annual ENETS Conference, 6 to 8 March 2019 in Barcelona, Spain, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2019 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.